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Abstract
Background: There are currently three postulated genomic subtypes of the childhood tumour neuroblastoma
(NB); Type 1, Type 2A, and Type 2B. The most aggressive forms of NB are characterized by amplification of the
oncogene MYCN (MNA) and low expression of the favourable marker NTRK1. Recently, mutations or high
expression of the familial predisposition gene Anaplastic Lymphoma Kinase (ALK) was associated to unfavourable
biology of sporadic NB. Also, various other genes have been linked to NB pathogenesis.
Results: The present study explores subgroup discrimination by gene expression profiling using three published
microarray studies on NB (47 samples). Four distinct clusters were identified by Principal Components Analysis
(PCA) in two separate data sets, which could be verified by an unsupervised hierarchical clustering in a third
independent data set (101 NB samples) using a set of 74 discriminative genes. The expression signature of six
NB-associated genes ALK, BIRC5, CCND1, MYCN, NTRK1, and PHOX2B, significantly discriminated the four clusters (p <
0.05, one-way ANOVA test). PCA clusters p1, p2, and p3 were found to correspond well to the postulated subtypes
1, 2A, and 2B, respectively. Remarkably, a fourth novel cluster was detected in all three independent data sets. This
cluster comprised mainly 11q-deleted MNA-negative tumours with low expression of ALK, BIRC5, and PHOX2B, and
was significantly associated with higher tumour stage, poor outcome and poor survival compared to the Type
1-corresponding favourable group (INSS stage 4 and/or dead of disease, p < 0.05, Fisher’s exact test).
Conclusions: Based on expression profiling we have identified four molecular subgroups of neuroblastoma, which
can be distinguished by a 6-gene signature. The fourth subgroup has not been described elsewhere, and efforts
are currently made to further investigate this group’s specific characteristics.
Background
Neuroblastoma (NB) is a childhood tumour of the sym-
pathetic nervous system, and is the most common can-
cer diagnosed during infancy. The prognosis of NB
patients depend upon clinical factors as stage [1], age at
diagnosis [2], tumour histopathology [3], and several
genetic factors as MYCN amplification (MNA) status [4]
and DNA index [5]. Generally, children diagnosed
before the age of 18 months with a localized tumour
have a favourable outcome, whereas older children with
metastasised tumours show poor prognosis and low
survival rate. However, MNA is proven to be strongly
associated with rapid progression and poor prognosis in
all patients despite age and stage of disease [4,6] and is
therefore central to the risk stratification system in all
clinical trial groups [7]. It is still important to emphasize
that the majority of metastatic tumours do not show
amplification of the MYCN oncogene, and other
chromosomal aberrations are being evaluated for the
International Neuroblastoma Risk Group (INRG) classi-
fication system [8].
Studies show that sporadic NB tumours can be
assigned to three major subtypes based on their
genomic profile, and these molecular signatures also
categorize risk groups of NB patients [9]. Type 1 com-
prise low-risk tumours with triploid DNA content,
numeric alterations, and high expression of the nerve
growth factor TrkA [10,11], Type 2A involve intermedi-
ate-risk tumours with high occurrence of 11q-deletion
(del11q) and 17q gain (gain17q) but no MNA, and Type
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high occurrence of gain17q and 1p-deletion (del1p)
[12,13]. The outcome prediction of intermediate-risk
tumours still remains uncertain and some tumours can-
not be definitively assigned to any of the three major
groups, indicating this division to be only broadly
outlined.
Genome-wide transcriptome microarray analysis
enables the possibility to investigate the expression of all
genes in a tumour simultaneously. De Preter and collea-
gues established a 132-gene classifier that discriminates
the three major genomic NB subtypes reflecting inher-
ent differences in gene expression between these sub-
types [14]. Several studies have established predictive
gene signatures of NB tumours [14-20], and others have
focused on the differential expression of genes between
tumour subsets [21-29]. The three genes MYCN [30],
ALK [31], and PHOX2B [32] have been directly linked
to NB pathogenesis; MYCN is amplified in a subgroup
of aggressive metastasizing tumours, activating muta-
tions of ALK or amplification is seen in approximately
7% of sporadic cases [33,31,34-37], and PHOX2B is
mutated in a subset of familial cases and in a small per-
centage of sporadic cases [32,38].
In the present study, we explored subtype discoveries
by unsupervised expression profiling using Principal
Components Analysis (PCA). The analyses identified
four distinct PCA clusters in two independent data sets,
which were verified in a third larger data set by PCA
and unsupervised hierarchical clustering. This study pre-
sents a new alternative way of subtype discrimination
which will hopefully facilitate the search for subtype-
specific therapeutic targets and the development of per-
sonalized medicine for children with neuroblastoma.
Results
Subtype discovery by PCA
Principal Components Analysis (PCA) was performed
on Affymetrix HU133A expression profiles from 17 [22]
and 30 [25,39] samples, respectively. Using variance fil-
tering, four distinct clusters appeared (p1-p4, Figure 1).
Among the 414 (De Preter data set) and 716 (McArdle/
Wilzén data set) genes which defined the clusters in the
two test data sets, 226 genes overlapped between the
two gene lists (Additional file 1). By cross-validation
using a “leaving-one-out” strategy we found our cluster
assignments to be relatively stable with only a few
exceptions. The De Preter data set showed instability of
three samples which shifted cluster belonging in up to
30% of cross-validations. The McArdle/Wilzén data set
showed instability of two samples which shifted cluster
belonging in one out of 30 cross-validations, respec-
tively. In order to check the robustness of the clustering
we made use of the cortex (n = 3) and neuroblast
samples (n = 3) from the De Preter data set which were
investigated by PCA in relation to the 17 NB samples.
As expected, the three cortex samples formed a distinct
cluster separated from the neuroblasts and NB tumour
samples (Additional file 2).
By Fisher’s exact test, MNA and del1p were found to
be significantly more frequent in PCA cluster p3 (p =
0.018 and p = 3.9E-04, Fisher’s exact test, table 1, Figure
2A). High stage (INSS stage 3-4), poor outcome, and
gain17q were observed in higher frequencies in PCA
clusters p2, p3 and p4 (Figure 2A) compared to cluster
p1. The frequency of del11q was considerably higher in
PCA clusters p2 (data set 2 p = 0,012, Fisher’s exact
test, table 1) and p4 (p = 0.05, Fisher’s exact test, data
set 1, table 1). Nineteen out of 47 tumours from both
data sets showed del11q, and among those 14 were
found in PCA clusters p2 and p4 (Figure 2A).
With the intention to explore the expression of genes
that have previously been associated with NB, we per-
formed a mining of gene lists from literature. Starting
with 15 gene lists [14-16,18-29], 212 genes were found
to be present in at least two of the lists, and among
those 157 were present in all three data sets (Additional
file 3). A PubMed search was performed on the Gene
Symbol in co-occurrence with the terms “neuroblas-
toma” and “gene expression” (Additional file 4) resulting
in 30 genes with hits in PubMed. Out of these 30 genes,
six NB-associated genes were selected; i) the pre-dispo-
sition genes ALK and PHOX2B,i i )MYCN and
CCND1which are amplified in 20-35% and 3-6% of
sporadic neuroblastomas respectively [13,30,40], and iii)
NTRK1 and BIRC5 w h i c hh a v eb e e nf o u n dt ob ed i f f e r -
entially expressed between subsets of NB [41,42]. All six
NB-associated genes were found to be differentially
expressed between PCA clusters (Figure 1), which was
statistically confirmed by a one-way ANOVA (table 1)
and a multiple comparison post-hoc test (Additional file
5). ALK and BIRC5 were found to be up-regulated in
cluster p3 (fold > 2.5) and these genes also showed ele-
vated expression in cluster p2. This was in contrast to
clusters p1 and p4 in which ALK and BIRC5 were found
to be down-regulated (table 1, table 2). Also, a 5 times
up-regulation of MYCN was found in cluster p3 in com-
parison to clusters p1 or p4. The opposite effect was
found for NTRK1 which was highly expressed in cluster
p1 (10-fold, table 1) and specifically down-regulated in
cluster p3 (16-fold, table 1). Cluster p4 consistently
showed low expression of all six NB-associated genes
compared to the other clusters (table 1, table 2).
According to Kaplan-Meier, overall survival (OS) and
event free survival (EFS) rates were significantly differ-
ent between the four clusters (OS p = 2.24E-04, EFS
p = 0.019, Log-rank, Mantel-cox). The lowest survival
probabilities were found in PCA clusters p3 and
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tively, and an EFS rate of 22.2% and 25% at 5 year
from diagnosis (Figure 2B). In contrast, none out of 14
patients with tumours belonging to PCA cluster p1
died from disease, and the survival probability in this
cluster was 100% at 5 years from diagnosis.
Verification by hierarchical clustering and PCA
In order to verify the existence of the four groups, a dis-
criminative gene set was defined and applied to a third
independent data set. First, the p-clusters in data sets 1
and 2 were integrated by reassignment of tumours
based on their 6-gene expression profile (r1-r4, Addi-
tional file 6). Rules for the r-group assignments were
defined by standard deviations (SD) of expression levels
and applied to both data sets. The r1-r4 representative
o ft h ep - g r o u pa s s i g n m e n t sw a sf o u n dt ob ev e r ys t a b l e
(table 3). However, three cases from the De Preter data
set and seven cases from the McArdle/Wilzén data set
could not be assigned to any r-group based on the rules,
resulting in two data sets of 14 and 23 tumour samples,
respectively. Next, four Significance Analysis of Microar-
ray (SAM) tests were performed by multiple compari-
sons on the two data sets separately. The four SAM
Figure 1 PCA plots of two parallel cluster analyses. Principal Components Analysis (PCA) of the two test groups using a variance cut-off of
0.4. A. HU133A De Preter data set (414 variables, 17 tumour samples, [22]). B. HU133A McArdle/Wilzén data sets (716 variables, 30 tumour
samples, [25,59]). Upper panel: PCA clusters, samples (spheres) are joined by nearest Euclidean neighbour. Lower panel: Expression of six NB
associated genes Red = High expression; Green = Low expression. The colour scale is based on standard deviations (SD) and ranges from +2 SD
(red) to -2 SD (green).
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pared to generate combined lists of overlapping genes.
From the overlapping lists, 30 genes with the highest
combined fold change for each of the four contrasts
were selected, generating a set of 98 genes. Out of the
98 genes, 74 were present in the third data set (Wang).
Third, unsupervised hierarchical clustering and PCA
was performed on the Wang data set using the 74 dis-
criminative gene set.
The unsupervised hierarchical clustering of the 101 NB
samples clearly divided tumour cases into four distinct
subgroups (Figure 3A). Ninety samples were clearly allo-
cated into one of the four hierarchical clusters (h1-h4)
based on the dendogram (Figure 3A), and the remaining
11 samples were assigned to a cluster based on the
nearest Euclidian neighbour in the PCA (Figure 3B). All
the 17 samples assigned to the hierarchical cluster 3
(h3) were stage 4, MYCN amplified tumours with high
frequency of del1p (Figure 3A, table 4). Samples
assigned to hierarchical clusters h2 and h4 consisted of
high stage tumours (stage 3-4) with high frequency of
del11q without MYCN amplification, thus corresponding
to the genomic subtype 2A (table 4). Tumours of clus-
ters h2, h3, and h4 all show high content of gain17q.
Patients of cluster h3 showed the worst outcome, with
1 0o u to f1 6d e a do fd i s e a s e( 2w e r el o s tf o rf o l l o wu p )
and a survival probability of 36.5% at 5 years from diag-
nosis (Figure 3C). Patients of cluster h2 also showed a
worse outcome, with 10 out of 25 dead of disease and
an OS rate of 58.4% at 5 years from diagnosis. In the
fourth cluster h4, 3 out of 14 patients died from the dis-
ease (6 patients were lost for follow-up), and showed an
OS probability of 50.5% at 5 years from diagnosis. The
lowest death and relapse rates were seen in hierarchical
cluster h1, which showed a 91.1% OS rate and an 88.9%
EFS rate at 5 years from diagnosis (Figure 3C). A PCA
of the 74 discriminative gene set in the 101 samples
shows that the hierarchical subdivision overlaps well
with INSS stage subdivision, and that the human fetal
brain sample clusters to the hierarchical group h4
(Figure 3B).
Five specific gene clusters (g1-g5) showing differential
expression in the four h-groups were noted (Figure 3A).
The eighteen genes in cluster g1 mainly involved ner-
vous system maintenance and developmental genes (e.g.
NTRK1, DBH), and those were highly expressed in the
favorable h1 group. The h2 and h3 groups showed high
expression of a gene cluster encoding cell cycle related
proteins (g2). Gene cluster 3 (g3) comprised MYCN as
well as nine MYCN/c-MYC downstream targets and
was highly expressed in the MNA-specific sample group
h3. The fourth gene cluster (g4) was specifically over-
expressed in tumours of the h4 group and comprised 22
genes which were all found to be involved in nervous
system development (e.g. ERBB3, GAS7, GPC3, SOX10),
nervous system maintenance (e.g. ATP1A2, COL9A3,
Table 1 Characteristics of the four PCA clusters(p1-p4)
Fisher’s exact test p1 p2 p3 p4
Data set 1
(n = 4)
Data set 2
(n = 10)
Data set 1
(n = 4)
Data set 2
(n = 10)
Data set 1
(n = 6)
Data set 2
(n = 5)
Data set 1
(n = 3)
Data set 2
(n = 5)
High stage (3 or 4) 0,053* 0,056 0,330 0,691 0,075 0,355 0,324 1,000
Stage 4 0,029* 0,001** 0,241 0,062 0,088 0,304 0,124 0,696
Outcome 0,139 0,051* 0,555 1,000 0,072 1,000 0,728 0,070
MNA 0,208 0,375 0,208 0,141 0,001** 0,003** 0,324 1,000
Del1p 0,088 0,210 0,088 0,067 0,018* 3,9E-04** 0,360 0,589
Del11q 0,441 0,235 0,559 0,013* 0,160 0,622 0,051* 0,622
Gain17q 0,063 0,128 0,365 0,109 0,058 1,000 0,458 0,651
ANOVA one-way ANOVA significance FC p1 FC p2 FC p3 FC p4
Data set 1 Data set 2 Data set: 1 2 Data set: 1 2 Data set: 1 2 Data set: 1 2
ALK 1,1E-03** 0,277 -1,8 -0,5 1,2 0,0 3,6 1,4 -1,0 -0,6
BIRC5 6,1E-06** 1,4E-05** -2,9 -1,7 2,9 2,0 7,8 2,1 -3,0 -2,6
CCND1 0,011* 0,003** 0,5 1,1 2,0 0,4 1,0 0,1 -1,9 -2,6
MYCN 2,0E-04** 7,0E-04** -0,6 -0,3 0,4 -0,4 12,6 2,4 -3,5 -1,4
NTRK1 6,7E-04** 1,1E-05** 3,7 3,4 3,6 0,7 0,1 -4,0 -0,3 -2,6
PHOX2B 0,006** 3,4E-08** 0,5 0,6 2,0 1,0 1,2 0,7 -2,3 -3,2
Fisher’s exact test: Each cluster (p1, p2, p3, or p4) versus the other clusters combined. n = the number of samples in each subgroup. High stage = INSS stage 3
and 4; outcome = dead of disease; MNA = MYCN amplification; del = deletion. Significance is marked by stars: * p < 0.05, ** p < 0.01. ANOVA one-way: The
differential expressions from six genes in PCA clusters (p1-p4) were tested by an ANOVA one-way test. Significance is marked by stars: * p < 0.05, ** p < 0.01. FC
= The log2 fold change of genes in each PCA group compared to the other groups combined.
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CAPN3, MT2A, SERPINA3, SGPL1). The fifth gene set
(g5) which was highly expressed in sample group h3,
and elevated in sample groups h2 and h4 (Figure 3A)
comprised five genes (ARHGEF10, CUX2, DUSP4,
LMO3, and PHGDH) with different functions.
Validation of PCA clusters and the 6-gene signature
A PCA of unfiltered global transcripts of the three data
sets clearly confirmed the existence of four distinct sub-
groups (Additional file 7). The PCA loadings from data
set 2 (McArdle/Wilzén) were utilized to plot the other
two data sets (De Preter and Wang). Next, a back-check
test was performed by using the PCA loadings from
data set 1 (De Preter) to plot the other two data sets
(McArdle/Wilzén and Wang).
Also, the 6-gene signature (ALK, BIRC5, CCND1,
MYCN, NTRK1,a n dPHOX2B)w a sv e r i f i e dt ob es u f f i -
cient for subtype discrimination of both the PCA
clusters (p1-p4) identified in data sets 1 and 2 (De Pre-
ter and McArdle/Wilzén) and the hierarchical clusters
(h1-h4) identified in the Wang data set (Figure 3).
Moreover, the 6-gene expression pattern seen in the
four hierarchical clusters corresponded well with the
expression pattern found in the four initial PCA clusters
(Figure 1 and Figure 4B). In addition, the 6-gene set
specifically separated the human fetal brain specimen
from the other NB tumour samples (Figure 4B), which
was in contrast to what could be when seen using the
74-gene set (Figure 3A). A comparison between the
expression-based p- and h- group assignments and the
genomic-based subtypes showed that the p1 cluster cor-
responded well to the favourable subtype 1, the p2 to
the 2A type, and the p3 to the MNA-specific subtype
2B (table 4). Most tumour cases of the p4 cluster were
found among the genomic subtype 2A, although a few
p4 cases were also found among other genomic subtypes
(table 4). Approximately the same pattern could be seen
Figure 2 Frequency of prognostic factors and survival probability in PCA clusters. A. The frequency of prognostic factors in the four PCA
clusters p1-p4 for the De Preter data set (n = 17) and McArdle/Wilzén (n = 30). High stage (3-4) = INSS stage 3 and 4; DOD = Dead of disease; MNA =
MYCN amplification; Del = deletion. Significant occurrence of prognostic factors in one PCA cluster compared to the others is marked with stars
(Fisher’s exact test). n = the number of samples in each subgroup. B. Kaplan Meier survival curves of PCA clusters (p1-p4) from three data sets (De
Preter, McArdle, and Wilzén). OS = Overall survival (n = 43). EFS = Event-free survival (n = 35). Chi-square significance by Log-rank (Mantel-Cox).
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ments of data set 3 (Wang) to the genomic subtypes
(table 4). However, in the Wang data set a considerable
higher number of cases assigned to the fourth cluster h4
were found among the favourable genomic subgroup
Type 1 (table 4).
In order to check the previously reported relationship
of the MYCN and c-MYC downstream effects we inves-
tigated the expression patterns of the MYC-target genes
in the four identified groups (p- and h-groups, Addi-
tional file 8). Pearson correlation tests showed MYCN
and c-MYC to be significantly negatively correlated in
all three data sets (table 5). MYCN was found to be spe-
cifically over-expressed in the MNA-specific group p3/
h3. In contrast, c-MYC over-expression could be seen in
a subset of tumours of the p1/h1, p2/h2, and p4/h4 sub-
groups, but not in any of the tumours assigned to the
MNA-specific group p3/h3. The expression pattern of
the MYCN/c-MYC downstream targets AHCY, DKC1,
FBL, GMPS, and PAICS were found to preferentially fol-
low the MYCN expression levels, and thus most highly
expressed in the p3/h3group. Also, a slightly elevated
expression of the MYCN/c-MYC downstream targets
could be seen in group p2/h2 (Additional file 8).
Discussion
A large number of publications prove that cancer can be
classified through gene expression profiling. Principal
components analysis (PCA) is a useful tool to reduce
t h ed i m e n s i o n so fd a t at ob ea b l et oi d e n t i f ya n dv i s u a -
lize hidden patterns. PCA has been widely used in gen-
ome expression studies to discriminate tumour
subtypes. For example, Yeoh and colleagues identified
prognostically important subtypes and a novel subgroup
of pediatric acute lymphoblastic leukaemia (ALL) by
PCA of gene expression data [43]. In order to develop
more effective and less toxic cancer treatment it is
necessary to identify and correctly classify the molecular
subtypes, as well as to unravel the underlying oncogenic
driving pathways for each type.
In the current study, subtypes of neuroblastoma were
explored by expression profiles from four microarray
studies [22,25,28,39]. In the first step, PCA was per-
formed on two independent data sets and four distinct
clusters were identified in both sets. Prognostic factors
such as high INSS stage, MNA, and del1p, differed sig-
nificantly between clusters. Three of the four clusters (i.
e. p1-p3) corresponded well to the previously established
genomic subtypes 1, 2A, and 2B. Remarkably, a fourth
novel cluster (p4) with a considerable different expres-
sion profile appeared independently in both data sets,
and has not been described elsewhere. This new cluster
was found to encompass mainly high stage tumours
with poor outcome and high frequency of del11q and
del1p, but low frequency of MNA. In data set 1 (De
Preter) all 3 cases assigned to cluster p4 were found to
be of clinical INSS stage 4, and in data set 2 (McArdle/
Wilzén) 3 out of 5 patients died from disease. However,
samples assigned to the p4 cluster showed a significantly
lower expression of MYCN and ALK compared to the
MNA-specific cluster p3 (table 2), which indicate an
alternative progression pathway within tumours assigned
to the fourth cluster.
In the second step, the existence of four groups could
be verified by an unsupervised hierarchical clustering
and PCA of a third data set (Wang data set [28]) using
a discriminative gene set of 74 genes from the first step.
All tumour samples assigned to the h3 cluster were
MNA tumours of clinical stage 4, and tumours assigned
to the h2 and h4 clusters comprised high stage tumours
with no MNA but with high content of del11q tumours.
The lowest survival probability and highest relapse rates
Table 2 Characteristics of cluster p4
Progn. factor p4 vs p1 p4 vs p2 p4 vs p3
High stage (3-4) 0,047988 * ↑ 0,48968 0,375645
Stage 4 0,002127 ** ↑ 0,583591 0,506192
DOD 0,009569 ** ↑ 0,296618 0,600782
Del1p 0,039341 * ↑ 0,009569 * ↑ 0,071035
MNA 0,566667 0,35 0,00905 ** ↓
Del11q 0,181631 0,291194 0,165635
Gain17q 0,212934 0,428148 0,31448
Transcript p4 vs p1 p4 vs p2 p4 vs p3
ALK 0,696703 0,403066 0,005545 ** ↓
BIRC5 0,042222 * ↓ 1,06E-06 ** ↓ 4,78E-06 ** ↓
CCND1 5,43E-05 ** ↓ 0,000243 ** ↓ 0,046452 * ↓
MYCN 0,036238 * ↓ 0,055719 ** ↓ 0,002016 ** ↓
NTRK1 0,001017 ** ↓ 0,03105 * ↓ 0,093904
PHOX2B 0,004037 ** ↓ 0,002773 ** ↓ 0,006196 ** ↓
Progn. Factor: Fischer’s exact test of frequency occurrence of prognostic factors
in group p4 compared to the other groups separately. High stage = INSS stage
3 and 4; DOD = Dead of disease; Del = deletion; MNA = MYCN amplification.
Transcript: T-test by Welch of differential expression in p4 compared to the
other groups separately. p-values from each data-set are combined (see text for
details). The arrows marks the direction: ↑ Higher frequency or higher
expression in p4, ↓ Lower frequency or lower expression in p4.
Table 3 r-groups vs. p-groups
r1 r2 r3 r4 ND
p1 9 1004
p2 1 10 003
p3 0010 01
p4 0006 2
Contingency table of r-groups and p-groups of the two test data sets (De
Preter and McArdle/Wilzén), 47 samples in total. The r-group assignment was
based upon MNA status, INSS stage and expression levels of the six NB-
associated genes with the highest PubMed search score (see additional file 4).
ND = Not determined. The p-group assignment was based upon the PCA
clusters (see text for details).
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Page 6 of 15Figure 3 Hierarchical clustering using a 74 discriminative gene set. A. Unsupervised hierarchal clustering of the Affymetrix HGU95Av2 Wang
data set (102 tumour samples in total [28]) by the 74-gene set. The heat map colour scale is based on standard deviations (sd) and ranges from +2 sd
(red) to -2 sd (green). The five gene clusters seen are named g1-g5. Status of eight prognostic factors is shown by black and white squares in the
lower part: Outcome = Dead of disease; MNA = MYCN amplification; Del = deletion. Black = event, White = No event, Light grey = Not determined.
INSS stage is marked as follows: Black = stage 4, dark grey = stage 3. The four hierarchical subgroups seen in the heat map are marked by colour dots:
Green = Hierarchical cluster 1 (h1), Orange = h2, Blue = h4, Red = h3, Grey = Human fetal brain. B. PCA plot of the 74-classifier gene-set. Left panel:
the four hierarchical clusters colour-coded according to the Hierarchical clustering (see above). Right panel: three INSS stages: Green = stage 1, Blue =
stage 3, Red = stage 4, Grey = Human fetal brain. C. Kaplan Meier survival curves of hierarchical clusters (h1-h4) from the Wang data set. OS = Overall
survival (n = 92). EFS = Event-free survival (n = 92). Chi-square significance by Log-rank (Mantel-Cox).
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in descending order (Figure 3C). A comparison between
the survival probabilities of the hierarchical and PCA
sub-divisions indicated that the h4 cluster constituted
less unfavourable tumours compared to those assigned
to the p4 cluster. The heterogeneous results seen
between data sets may be explained by the small
Table 4 Expression subgroups vs. Genomics subgroups
Data sets 1 & 2 (De Preter & McArdle/Wilzén)
p1 p2 p3 p4
Type 1 10 401
Type 2A 3 10 1 4
Type 2B 10 9 1 In total 47
Other 00 1 2
Data set 3 (Wang)
h1 h2 h3 h4
Type 1 21 409
Type 2A 15 15 0 7
Type 2B 01 18 1 In total 101
Other 25 0 3
Contingency table of p-group assignment and genomic subgroup assignment
of the two test data sets (De Preter and McArdle/Wilzén). The p-group
assignment was based upon the PCA clusters. The genomic subtypes were
established based on INSS stage, MNA status, and Del11q status (see text for
details). The highest numbers of cases of the p- and h-group assignments
falling into a specific genomic subgroup category are shown in bold.
Figure 4 Verification of 6-gene signature. A. PCA of the six NB associated genes ALK, BIRC5, CCND1, MYCN, NTRK1,a n dPHOX2B on three
data sets: De Preter (left panel), McArdle/Wilzén (middle panel), and Wang (right panel). Samples (spheres) in the two test data sets (De
Preter and McArdle/Wilzén) are coloured by the PCA clusters: Green = p1, Orange = p2, Red = p3, and Blue = p4. Samples (spheres) in the
Wang data set are coloured by the hierarchical subgroups: Green = h1, Orange = h2, Blue = h4, and Red = h3, Grey = Human fetal brain.
Human fetal brain (marked with an arrow) is distinct from the 101 NB samples. B. Expression heat map of the 6-gene signature of the Wang
data set. The colour scale is based on standard deviations (SD) and ranges from +2 SD (red) to -2 SD (green). Samples are presented in the
same order as in Figure 3A.
Table 5 Correlations MYCN and c-MYC
De Preter Sign. -,470
PCC ,057
N1 7
McArdle/Wilzén Sign. -,420*
PCC ,021
N3 0
Wang Sign. -,366**
PCC ,000
N 101
Pearson Correlations of MYCN and c-MYC for three data sets. Sign =
Significance ** p < 0.01 (2-tailed). * p < 0.05 (2-tailed). PCC = Pearson
correlation coefficient. N = number of samples.
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tumour cohorts. As for example, the Wang data set
does not include any clinical stage 2 tumours which
might indicate that the cases in this data set were not
randomly selected. This would of course affect the sub-
group characteristics and might explain the divergent
outcome seen in patient cohorts from the different data-
sets. Also, since the fourth subgroup (p4, h4) is a very
small group it is difficult to say if the frequencies of dif-
ferent genetic alterations are stably distributed between
the subgroups. Moreover, six patients of the h4 cluster
in the Wang data set were lost for follow up, which
makes it difficult to draw any major conclusions.
The hierarchical clustering also identified five gene
clusters. Nervous system developmental genes, including
NTRK1 and DBH w e r ef o u n dt ob eh i g h l ye x p r e s s e di n
the favourable tumour cluster h1. Cell-cycle related
genes including BIRC5, CCNB1 and MCM-genes were
found to be highly expressed in clusters h2 and h3. Not
surprisingly, the MYC gene cluster (g3) was specifically
found to be over-expressed in the MNA-specific group
h3. Westermann and colleagues recently defined a core
set of MYCN/c-MYC downstream target genes which
were associated with malignant progression in NB [44].
In line with their results, we found MYCN and c-MYC
to be significantly negatively correlated in all three data
sets. We also wondered whether the c-MYC over-
expression could be specifically connected to any of the
four groups. However a heat map showed the c-MYC
over-expression to be evenly distributed among all
groups except for the MNA-specific group p3/h3 (Addi-
tional file 8). The transcription factor LMO3 (LIM
domain only 3) found in gene cluster g5 has been signif-
icantly associated with a poor prognosis in NB [45].
This is concordance with the present study in which the
highest expression of LMO3 was found in the most
unfavourable tumour group h3. Interestingly, LMO3 has
been shown to interact and act as a co-repressor of p53
[46].
The fourth novel tumour group (h4) was found to be
characterized by high expression of several brain-specific
and nervous system developmental genes. The Erbb
receptors (e.g. Erbb3) and the SoxE family (Sox8, Sox9
and Sox10) are essential for development of the sympa-
thetic nervous system and the development of neural
crest cells. Interestingly, Leon and colleagues reported
that Sox10 and Phox2b act together with the NK2
homeobox Nkx2-1 to modify RET signalling and suggest
this interaction to contribute to HSCR (Hirschprungs
disease) susceptibility [47]. The growth arrest-specific 7,
Gas7, is regulated by Sox9 and the ERK1/2 MAP kinase
and is involved in chondrogenesis, and has been
reported to form a MLL/GAS7 fusion protein in a pedia-
tric case of B-cell acute lymphoblastic leukaemia [48]. In
addition, the g4 cluster comprised the suggested 3p
tumour suppressor gene SEMA3B [49]. The subgroup
discrimination properties of SEMA3B found in the pre-
sent study, as well as the significantly lower expression
observed in tumour groups p2/h2 and p3/h3, could sup-
port its tumour suppressor function.
The validation test of the four PCA clusters using
unsupervised and unfiltered global transcripts clearly
shows that the four subgroups exist in all three data sets
(Additional file 7). Moreover, the PCA of the 6-gene sig-
nature in all three data sets convincingly show that this
expression profile is sufficient for NB subtype discrimi-
nation (Figure 4A). Overall, our results indicate that the
most unfavourable group displaying MNA (correspond-
ing to Type 2B) and the most favourable group with
high NTRK1 expression (corresponding to Type 1) can
be easily discriminated by their expression profiles.
Moreover, our data indicates that the del11q tumours
(corresponding to Type 2A) are divided into at least two
expression subgroups (see table 4). Interestingly, the
existence of two del11q expression subgroups has
recently been reported by two other research groups
[23,50]. Fischer and colleagues studied the gene expres-
sion patterns of del11q tumours divided into two clinical
groups of favourable and unfavourable biology using
their previously described prognostic 144-gene expres-
sion classifier. They found that the clinical groups clus-
tered using unsupervised PCA and hierarchical
clustering [23]. Also, Buckley and colleagues identified a
15-miRNA signature that discriminates two distinct bio-
logical subtypes of del11q tumours [50]. Our current
study differs from these two studies in one important
aspect- it does not rely on any prior subtype division (e.
g. genomic subtypes, clinical groups etc.), which means
that it is entirely unbiased. As stated by Fischer and col-
leagues the 11q-deletion is most likely a secondary
event, and it is possible that the decision between
favourable and unfavourable neuroblastoma is made by
a yet undefined transformation event, for example ALK.
This hypothesis is completely consistent with our find-
ing, where ALK expression is significantly elevated in
subgroup p2/h2 (see Figure 1 and 4B). In order to clar-
ify and relate our subgroup discoveries to these recent
findings, we performed a PCA of the Wang data show-
ing tumours marked by their del11q status and coloured
by their h-group belongings (Figure 5). Deletion of 11q
was found to be distributed through all tumour groups
except for the MNA-specifich 3 - g r o u pi nw h i c ho n l y
two cases with 11q-deletion could be found (Figure 5A).
In line with Fischer et al. [23] we filtered out all cases
with MNA and/or del1p, and ended up with a PCA on
74 cases (Figure 5B). This left us with three expression
groups of del11q tumours, one favourable group (h1),
and two unfavourable groups (h2 and h4, see Figure
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Page 9 of 15Figure 5 Del11q groups of the Wang data set. Unfiltered PCA plots of the Wang data set (101 NB samples, 7542 genes). The four hierarchical
clusters (h-groups) in panels A-C (left) are colour-coded as follows: Green = h1, Orange = h2, Red = h3, Blue = h4. Del11q genetic aberrations in
panels A-C (right) are colour-coded as follows: Black = 11q-deletion, off-white = No 11q-deletion, White = Undetermined. A. PCA of all 101
neuroblastoma cases. B. PCA of 74 cases without MNA and Del1p C. PCA of 55 cases of the hierarchical groups h1 and h2 without MNA and
Del1p.
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group, leaving us with two groups of del11q tumours,
one favourable (h1) and one unfavourable (h2). These
results suggest that our subgroup discoveries are not
contradictory to the findings by Fischer et al. [23] and
Buckley et al. [50], but rather indicate that there are
three del11q expression subgroups instead of two; one
favourable with high NTRK1 expression (h1), one unfa-
vourable with high ALK, BIRC5 and CCND1 expression
(h2), and one smaller group (h4) characterized by high
expression of nervous system developmental genes (e.g.
ERBB3, SOX10).
The discriminative power of the six NB genes
strengthen the fact that these genes are indeed important
in neuroblastoma development. ALK was recently recog-
nized as the NB predisposition gene and has thereafter
also been found to be affected in sporadic tumours, either
though mutations of the tyrosine kinase domain or by
genomic amplification [31,34-37]. Interestingly, Passoni
and colleagues investigated the ALK expression and pro-
tein phosphorylation status and found that over-expres-
sion of either mutated or wild-type ALK defines poor
prognosis patients [51]. In this study, we found elevated
expression of ALK in the p2/h2 group, and the highest
expression level was found in the MNA-specific group
p3/h3. Moreover, various cell-cycle related genes, includ-
ing BIRC5 and CCND1, were found to be highly
expressed in sample groups p2/h2 and p3/h3, but low in
group p4/h4. The CCND1 gene region on 11q has been
shown to be amplified in a subset of primary neuroblastic
tumours [13,40], and several cases have been found to
show an extensive over-expression of cyclin D1 which
correlates with histological subgroups [52]. Moreover,
CCND1 is used as a marker for minimal residual disease
of NB [53]. The anti-apoptotic gene BIRC5 (also known
as survivin) is located in the often gained region on 17q
(gain17q), and has previously been found to be associated
with poor prognostic factors and low survival probability
in NB [41,54]. Recently, Eckerle and colleagues found
that BIRC5 is a direct transcriptional target of activating
E2Fs, and that BIRC5 is indirectly induced by N-myc
[55]. These findings are supported by the significantly
higher expression of both BIRC5 and MYCN found in
tumour group p3/h3 in the current study. Moreover, an
elevated expression of BIRC5 was found in sample group
p2/h2, and a significant down-regulation of both MYCN
and BIRC5 was found in group p4/h4 (p < 0.05, Welch t-
test). The MNA-specific p3/h3 group was also character-
i z e db yav e r yl o we x p r e s s i o no fNTRK1,w h e r e a st h e
favorable tumour group p1/h1 showed the highest
expression of NTRK1. TrkA (or NTRK1) is a well-known
marker of favorable NB tumours and its expression has
been linked to several cancer forms [56].
Conclusions
In conclusion, by expression profiling of 148 NB
tumours from four different Affymetrix-based microar-
ray studies, our data suggest the existence of at least
four molecular subgroups of neuroblastoma tumours.
Three of the expression-based tumour groups corre-
sponded well to the previously postulated genomic sub-
types and a fourth novel group was identified which has
not been described elsewhere. The novel tumour group
comprised high-stage 11q-deleted tumours with low
expression of ALK and MYCN, but high expression of
various CNS and nervous system developmental genes.
Our findings suggest an alternative classification system
based on expression profiling of a 6-gene signature.
Further studies of the novel subgroup’s specific charac-
teristics are warranted, and will hopefully lead to discov-
eries on new specific therapeutic targets for children
with neuroblastoma.
Materials and methods
Data pre-processing
Raw data files from four published neuroblastoma
expression microarray studies generated from two differ-
ent platforms (i.e. three data sets run on the Affymetrix
HU133A platform [22,25,39], and one data set generated
from the Affymetrix HGU95Av2 platform [28]) were
obtained from ArrayExpress http://www.ebi.ac.uk/micro-
array-as/ae/ and Gene Expression Omnibus http://www.
ncbi.nlm.nih.gov/geo/ and reanalyzed. The data were
pre-processed in three separate groups; i, Data set 1 (De
Preter data set) comprising profiles from 23 NB
tumours, preamplified and run on the HU133A plat-
form, ii, data set 2 (McArdle and Wilzén data set) com-
prising 30 neuroblastic tumours run on the HU133A
(not preamplified), iii, data set 3 (Wang data set) com-
prising 101 NB tumours and one brain tissue sample
run on the HGU95Av2. Bioconducter for R 2.9.2 (library
BioC 2.4) was used to perform gcRMA normalisation on
each data set separately [57]. For each probe-set, the
maximum expression value over all samples was deter-
mined, and probe-sets which showed very low or no
detectable expression levels were filtered out (max log2
expression <6). Next, the mean log2 expression level for
each Gene symbol was calculated, resulting in 7439
genes for data set 1, 8106 genes for data set 2, and 7542
genes for data set 3.
Principal Components Analysis (PCA)
Principal Components Analysis (PCA) was performed
using Omics Explorer 2.0 Beta from Qlucore http://
www.qlucore.se on data sets 1 and 2 separately. Using
the filtering variance slider, genes with the lowest var-
iance were filtered out until a distinct pattern of groups
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ables for test group 1 and a set of 716 variables for test
group 2 (variance cut-off was approximately 0,4 in both
data sets). Next, samples were joined to the nearest
neighbour using Euclidean distances of all active sam-
ples, and clusters of connected samples were defined as
separate PCA sample groups. These were cross-validated
by a “leaving-one-out” strategy. The eigenvectors of
genes included in the variance-filtered PCA for each
data set were sorted according to their loadings in Prin-
cipal component 1, 2, and 3 (PC1, PC2, and PC3)
respectively, and gene lists were compared between the
two test groups (Additional file 1).
PubMed gene list
In order to identify known genes which have previously
been identified as predictive or differentially expressed
in NB disease, the literature was reviewed and gene lists
from 15 neuroblastoma expression studies were selected
according to the following: 16 differentially expressed
genes from Albino et al., 2008 [21], the 55 PCA-based
gene module from Asgharzadeh et al., 2006 [15], the
132 PAM classifier gene set from De Preter et al., 2009
[14], 191 differentially expressed genes from De Preter
et al., 2006 [22], 220 differentially expressed genes with
a fold change above 2 from Fischer et al., 2010 [23], 18
differentially expressed genes from Fischer et al., 2006
[24], the 31 transcripts most strongly associated with
the major genetic subtypes of neuroblastoma from
McArdle et al., 2004 [25], the 38 top-ranked PAM clas-
sifying genes from Oberthuer et al., 2007 [18], the 144
PAM predictor set from Oberthuer et al., 2006 [16], the
41 top-ranked predictive genes from Ohira et al., 2005
[19], the 133 top-ranked genes from Schramm et al.,
2005 (from both SAM and PAM analyses) [26], the 89
top-ranked differentially expressed genes from Thorell
et al., 2009 [27], 155 differentially expressed genes from
Wang et al., 2006 (genes differentially expressed on
1p36 and 11q23, and genes from hierarchical clustering)
[28], 72 differentially expressed genes from Warnat et
al., 2007 [29], 59 genes selected by data-mining from
Vermeulen et al., 2009 [20] (Additional file 4). The
intersection of these gene lists resulted in a total num-
ber of 1012 unique genes, and among those the genes
that occurred in at least two of the 15 gene lists were
selected (212 genes, see Additional file 3.). Out of the
212 genes, 157 genes expressed in all three data sets
were selected for further co-occurrence search in
PubMed. Search terms were the following: “Gene Sym-
bol"[TIAB] AND “Gene expression"[MeSH Terms] AND
“neuroblastoma"[MeSH Terms] (search1, Additional file
4), and resulted in hits for 30 genes. In order to get a
fair number of PubMed scores we redid the same search
including gene alias names for all 30 genes according to
Gene cards http://www.genecards.org/ (search 2, Addi-
tional file 4). Based on the PubMed results and biologi-
cal relevance we selected six NB-associated genes from
the 30 high score gene list; ALK, BIRC5, CCND1,
MYCN, NTRK1 and PHOX2B.
Statistical analysis and subtype discrimination
The frequency of prognostic marker, i.e. INSS stage,
outcome, del1p, MNA, del11q, and Gain17q was calcu-
lated for each PCA subgroup and tested for significance
using Fisher’s exact test (table 1). The discriminative
power of the six NB-associated genes were tested for
significance using a one-way ANOVA test (table 1) and
a post hoc (Tukey) test for multiple comparisons. The
differential expressions between subgroups were also
investigated by Welch t-test (2 sample comparison,
unequal variance, table 2). A combined statistic for each
gene from the two data sets was constructed as a linear
combination of the z-scores (inverse normal distribution
of transformed p-values) weighted by the square root of
the data sets samples size proportion.
The genomics subtypes were defined based on INSS
stage, MNA status, and del11q status (table 4). All
tumour cases with MNA were assigned to subtype 2B, all
cases displaying del11q with no MNA were assigned to
subtype 2A, and all tumours of INSS stage 1, 2, or 3 with
no MNA and/or del11q and/or del1p and/or del3p, and
which were not dead of disease were assigned to the
favourable subtype 1. Tumours that did not fall into any
of the categories stated were termed “other” (table 4).
Verification by hierarchical clustering
In order to identify a subgroup discriminative gene set,
the 98 most differentially expressed genes between sub-
groups were identified by SAM. First, the p- group
assignments from the two data sets were translated by
reassignment into four integrated groups (r1-r4) defined
by rules for expression levels of the six NB genes (Addi-
tional file 6). Based on these rules, ten samples (three
from the DePreter data set and seven from the McAr-
dle/Wilzén data set) could not be assigned to any r-
group, which resulted in two sets of 14 and 23 tumours
respectively (Additional file 6). A 2 × 2 contingency
table shows the r1-r4 representative of the p1-p4 cluster
assignment (table 3). From each independent data set
the r1-r4 groups were analyzed by SAM using multiclass
comparison (i.e. each group was compared to the other
groups combined, resulting in four contrasts) [58]. The
4000 most significant genes with a fold change above 2
were selected in each independent data set. Next, SAM
gene-lists from the two data sets were compared to cre-
ate a list of overlapping (or common) genes from each
specific contrast. Probe sets with hybridization to more
than one gene were filtered out, which resulted in a
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lists from both data sets. For each gene and contrast,
t h em e a nl o g 2f o l dc h a n g ef r o mt h et w od a t as e t sw a s
calculated. Next, the genes with the highest combined
fold change in each contrast (n = 30) were selected,
resulting in a list of 98 unique genes.
The existence of molecular clusters was verified by an
unsupervised hierarchical clustering of a third indepen-
dent data set (Wang data set, comprising 102 samples,
[28]). Out of the 98 discriminative genes, 74 genes were
present on the Affymetrix HGU95Av2 platform as well
as expressed among the 102 samples. Hierarchical clus-
tering of both samples and genes was done using the
Average linkage of Euclidian metric (Pearson correla-
tion) for which each variable has been normalized to
mean 0 and variance 1. Samples were divided into hier-
archical groups based on the dendogram. Samples that
allocated in between dendogram trees were assigned to
a cluster based on the nearest euclidian neighbour in
the PCA-output.
Validation of PCA
In order to verify that the four identified groups could
be recognized and discriminated in all three data sets
we performed PCA using the same Principal Compo-
nents loadings. PCA was performed using the R func-
tion prcomp on unfiltered expression data, and PCA
plots were visualized in 3D using MatLab R2009a. Prior
to the analyses, the three pre-processed data sets were
filtered to contain the same set of genes (4728 genes in
total) and each gene was normalized to center around
zero with unit variance.
In the first test, a PCA was performed using the
McArdle/Wilzén data (data set 2) and the loading scores
from the first three Principal Components were plotted
using different colours for each previously identified
group (p1-p4 in data sets 1 and 2, and h1-h4 in data
set3, see Additional file 7). Next, the loadings from the
McArdleWilzén data set were applied to the De Preter
and Wang data sets to examine if the same Principal
Components (PC1-3) could discriminate the four
groups.
In the second test, we repeated the analysis starting
with a PCA on the De Preter data set, and the loadings
from the De Preter data were then applied to the McAr-
dle/Wilzén and Wang data sets to check if the same
pattern appeared (Additional file 7).
Survival analyses by Kaplan Meier
The Overall survival (OS) and Event-free survival (EFS)
of patients assigned to the four PCA subgroups (p1-p4)
from the two test data sets (De Preter, McArdle/Wilzén)
were analysed by Kaplan Meier. OS included totally 43
samples and 4 patients were lost for follow up (3 in p2,
and 2 in p3). EFS included totally 35 samples and 11
patients were lost for follow up (5 in p1, 3 in p2, 2 in
p3, and 2 in p4). Also, OS and EFS analyses of patients
assigned to the four hierarchical subgroups (h1-h4)
from the Wang data set were analysed by Kaplan Meier.
The OS and EFS analyses included totally 92 samples
and 9 patients were lost for follow up (1 in h1, 2 in h3,
and 6 in h4). The OS significance was calculated by chi-
square Log-rank (Mantel-Cox), and the five year survival
significance was calculated by Fisher’s exact test.
Additional material
Additional file 1: PCA loadings from the De Preter and McArdle/
Wilzén data set. Column 1-6: Variables (genes/probe-sets) and their PCA
loadings for Principal components 1, 2, and 3 (PC1, PC2, PC3) in data-set
1 and 2 (De Preter and McArdle/Wilzén respectively). Common variables:
Genes/probe-sets that were present in the PCA analysis of both data-
sets.
Additional file 2: PCA of cortex, neuroblast and NB samples.
Unfiltered Principal Components Analysis (PCA) of the De Preter data set
(7438 variables, 23 samples. Colour codes of spheres: Red =
neuroblastoma tumour specimens; Blue = Neuroblasts; Green = Cortex.
Additional file 3: Workflow of the study. Step 1: Subtype discovery by
unsupervised PCA of two data sets (De Preter and McArdle/Wilzén) from
three microarray expression studies (upper panel). Data-mining of gene
lists from literature, resulting in the selection of 6 NB-associated genes
(lower panel). Step 2: Defining the 74-gene subtype discrimination gene
set by SAM (upper panel). Verification of subgroup existence by
hierarchical clustering and PCA in a third data set (Wang) using the 74-
gene set (lower panel).
Additional file 4: Gene lists from literature & hits in PubMed. A. List
of 15 expression studies used for the data-mining. B. PubMed searches
of 157 and 30 genes respectively. PubMed searches were performed as
follows: Search 1(left): 157 genes, search term “Gene Symbol"[TIAB] AND
“Gene expression"[MeSH Terms] AND “neuroblastoma"[MeSH Terms].
Search 2 (right):30 genes, search term “Gene Symbol"[TIAB] OR “Alias
name"[TIAB]) AND “Gene expression"[MeSH Terms] AND
“neuroblastoma"[MeSH Terms]. The six NB-associated genes ALK, BIRC5,
CCND1, MYCN, NTRK1, and PHOX2B were selected for further analysis (see
text for details).
Additional file 5: Multiple comparisons by Post hoc test (Tukey).
Gene expression of ALK, BIRC5, CCND1, MYCN, NTRK1, and PHOX2B in PCA
clusters p1-p4 of the two data sets De Preter (left) and McArdle/Wilzén
(right) was analysed by a Post-hoc test (Tukey). Significance level is
marked by a grey colour scale.
Additional file 6: Rules and assignments of r-groups. Rules for r-
group assignments (upper table): Groups (r1-r4) were defined based on
the standard deviation (sd) of expression for the six NB-associated genes.
R-Assignments of samples from data set 1 and 2 into r-groups (lower
table): Expression sd intervals of 5 out of 6 genes had to be in
agreement with the rules for each r-group in order to be categorized.
Additional file 7: PCA validation of p- and h-groups using unfiltered
expression data. Principal Components Analysis (PCA) of unfiltered
global expression data (4728 genes) from three data sets (De Preter,
McArdle/Wilzén, and Wang). A. PCA plotted by loadings generated from
the McArdle/Wilzén data set. B. PCA plotted by loadings generated from
the De Preter data set. Cases (spheres) are coloured by their group
assignments: Green = p1/h1, Orange = p2/h2, Red = p3/h3, Blue = p4/
h4.
Additional file 8: Expression heat map of MYCN, c-MYC and MYCN/
c-MYC downstream targets. The two test data sets De Preter (n = 17,
Upper left panel) and McArdle/Wilzén (n = 30, lower left panel) are
divided into four PCA clusters (p1-p4), and the verification data set Wang
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Page 13 of 15(n = 102, right panel) is divided into four hierarchical clusters (h1-h4).
The heat-map colour scale is based on standard deviations (sd) and
ranges from +2 sd (red) to -2 sd (green). Status of prognostic factors is
shown by black and white squares to the right of each panel. Stage/
DOD: Black = INSS stage 4 or dead of disease, Dark grey = INSS stage 3,
White = Low INSS stage (stage 1 or 2) and alive, Light grey = Not
determined.
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